JERUSALEM, July 9 (Xinhua) — The Sheba Medical Center in central Israel and the U.S. medical technology company Immunicom announced Thursday the initiation of a groundbreaking clinical trial to evaluate the clinical effectiveness of a new oncology treatment.
The new treatment approach neutralizes cancer’s ability to block the patient’s natural immune defense mechanisms, which are usually exhausted when the patient is suffering from metastatic disease.
The approach is based on selective extraction of soluble proteins that shield tumors, to activate the patient’s immune system to fight cancer aggressively.
The treatment includes a plasma filtration device as a monotherapy, and in combination with an immune checkpoint inhibitor.
Utilizing a process similar to dialysis, the new therapy developed by the U.S. company is a non-pharmaceutical solution for treating cancer by using the device to remove the harmful excess of immune-suppressive inhibitors.
These inhibitors are produced by cancers to block the natural immune response to kill tumors.
The 40-patient clinical study will treat resistant metastatic melanoma, breast cancer, renal cell carcinoma and non-small cell lung cancer patients.
Immunicom, founded in 2013 and located in San Diego, California and Houston, Texas, focuses on developing innovative, non-pharmaceutical approaches for treating cancers, inflammatory diseases and autoimmune diseases.
Immunicom’s blood-filtering technology has the potential to effectively treat a wide variety of cancer types. Enditem